NEWS DESK
Building your stock news briefing…
Amgen Inc. - Common Stock (AMGN) is currently showing a slightly bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
/PRNewswire/ -- Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Европейская комиссия (ЕК) выдала регистрационное удостоверение на препарат IMDYLLTRA
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
Most people think you can't time the market. That's nonsense.
This section is separated from the general news feed so investors can quickly connect the latest headlines with the structured earnings report.
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis THOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Amgen recently secured European Commission approval for its drug Imdylltra, targeting early-stage small cell lung cancer. This regulatory milestone marks a significant development for the company, potentially expanding its oncology portfolio and market reach in Europe. While the approval is encouraging, details about Imdylltra's commercial potential and competitive positioning remain to be seen. Amgen's presentation at the Jefferies Global Healthcare Conference may provide further insights into its strategic direction and pipeline progress. The stock currently trades in a mixed range, reflecting cautious investor sentiment amid these updates and an uncertain earnings outlook. Traders may watch for follow-up news on Imdylltra's launch plans and clinical data to gauge future momentum.
AMGN is not giving a fully clean trend read right now, which makes the quality of follow-through especially important.
Momentum is not especially stretched right now, so price behaviour around fresh headlines may matter more than an extreme oscillator reading.
Last price is $325.98, versus MA50 at — and MA200 at —. Relative to those reference points, AMGN is — vs MA50 and — vs MA200.
/PRNewswire/ -- Компания Amgen (NASDAQ: AMGN) сегодня объявила, что Европейская комиссия (ЕК) выдала регистрационное удостоверение на препарат IMDYLLTRA
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.
Most people think you can't time the market. That's nonsense.